AKT1 and acute myeloid leukemia: Western blot analysis of combination treated AML blasts showed a small increase in client protein AKT knockdown and also interestingly, up regulation of IKBα (a repressor of the pro-survival protein NFκB known to confer drug resistance in AMLs [26]) and reduced HSP70 induction in response to combination treatment compared to an equivalent dose of ganetespib alone.